Literature DB >> 21693601

What is causing active trachoma? The role of nonchlamydial bacterial pathogens in a low prevalence setting.

Matthew J Burton1, Victor H Hu, Patrick Massae, Sarah E Burr, Caroline Chevallier, Isaac A Afwamba, Paul Courtright, Helen A Weiss, David C W Mabey, Robin L Bailey.   

Abstract

PURPOSE: In low prevalence settings, clinically active follicular trachoma (TF) is often found in the absence of detectable Chlamydia trachomatis. The reasons for this persistent follicular phenotype are not well understood; one possible explanation is that other bacterial species are provoking the inflammatory response. This study investigated the relationship between TF, C. trachomatis, and nonchlamydial bacterial infection.
METHODS: A cross-sectional survey was conducted in a trachoma endemic village in Tanzania. All available children were examined for trachoma and swabs were collected for microbiologic culture (blood and chocolate agar) and C. trachomatis PCR (Amplicor).
RESULTS: Four hundred seventy-three children under 10 years of age were recruited for this study. The prevalences of TF and C. trachomatis were 13.7% and 5.3%, respectively, and were not associated. Bacteria were cultured from 305 (64.5%) swab samples; 162 (34.3%) grew a pathogen (with or without a commensal organism) and 143 (30.2%) grew commensal bacteria only. The most common pathogens were Streptococcus pneumoniae and Haemophilus influenzae (type B and non-type B). The presence of bacterial pathogens was associated with TF (odds ratio, 4.68; 95% confidence interval, 2.31-9.50; P < 0.001).
CONCLUSIONS: In regions with low levels of endemic trachoma, it is possible that much of the TF that is observed is attributable to nonchlamydial bacterial pathogens. It is plausible that individuals who have previously developed a follicular conjunctivitis in response to C. trachomatis may more readily reform conjunctival follicles when challenged with certain other bacterial species.

Entities:  

Mesh:

Year:  2011        PMID: 21693601      PMCID: PMC3176035          DOI: 10.1167/iovs.11-7326

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  24 in total

1.  Alterations in the conjunctival bacterial flora following a single dose of azithromycin in a trachoma endemic area.

Authors:  K C Chern; S K Shrestha; V Cevallos; H L Dhami; P Tiwari; L Chern; J P Whitcher; T M Lietman
Journal:  Br J Ophthalmol       Date:  1999-12       Impact factor: 4.638

2.  The duration of human ocular Chlamydia trachomatis infection is age dependent.

Authors:  R Bailey; T Duong; R Carpenter; H Whittle; D Mabey
Journal:  Epidemiol Infect       Date:  1999-12       Impact factor: 2.451

3.  A simple system for the assessment of trachoma and its complications.

Authors:  B Thylefors; C R Dawson; B R Jones; S K West; H R Taylor
Journal:  Bull World Health Organ       Date:  1987       Impact factor: 9.408

4.  Clinical activity and polymerase chain reaction evidence of chlamydial infection after repeated mass antibiotic treatments for trachoma.

Authors:  Jeremy D Keenan; Takele Lakew; Wondu Alemayehu; Muluken Melese; Travis C Porco; Elizabeth Yi; Jenafir I House; Zhaoxia Zhou; Kathryn J Ray; Nisha R Acharya; John P Whitcher; Bruce D Gaynor; Thomas M Lietman
Journal:  Am J Trop Med Hyg       Date:  2010-03       Impact factor: 2.345

5.  Field evaluation of a rapid point-of-care assay for targeting antibiotic treatment for trachoma control: a comparative study.

Authors:  Claude-Edouard C Michel; Anthony W Solomon; Jose P V Magbanua; Patrick A Massae; Ling Huang; Jonaice Mosha; Sheila K West; Elpidio C B Nadala; Robin Bailey; Craig Wisniewski; David C W Mabey; Helen H Lee
Journal:  Lancet       Date:  2006-05-13       Impact factor: 79.321

6.  Bacteriological studies on trachomatous and normal persons from three areas on Taiwan.

Authors:  R L Woolridge; J D Gillmore
Journal:  Bull World Health Organ       Date:  1962       Impact factor: 9.408

7.  Normal ocular flora in healthy eyes from a rural population in Sierra Leone.

Authors:  J A Capriotti; J S Pelletier; M Shah; D M Caivano; D C Ritterband
Journal:  Int Ophthalmol       Date:  2008-02-23       Impact factor: 2.031

8.  Pathway-focused arrays reveal increased matrix metalloproteinase-7 (matrilysin) transcription in trachomatous trichiasis.

Authors:  Martin J Holland; David Jeffries; Michael Pattison; Gerit Korr; Alevtina Gall; Hassan Joof; Ahmed Manjang; Matthew J Burton; David C W Mabey; Robin L Bailey
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-04-07       Impact factor: 4.799

9.  Two doses of azithromycin to eliminate trachoma in a Tanzanian community.

Authors:  Anthony W Solomon; Emma Harding-Esch; Neal D E Alexander; Aura Aguirre; Martin J Holland; Robin L Bailey; Allen Foster; David C W Mabey; Patrick A Massae; Paul Courtright; John F Shao
Journal:  N Engl J Med       Date:  2008-04-24       Impact factor: 91.245

10.  Bacterial infection and trachoma in the gambia: a case control study.

Authors:  Matthew J Burton; Richard A Adegbola; Fabakary Kinteh; Usman N Ikumapayi; Allen Foster; David C W Mabey; Robin L Bailey
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-10       Impact factor: 4.799

View more
  42 in total

1.  Active trachoma is associated with increased conjunctival expression of IL17A and profibrotic cytokines.

Authors:  Matthew J Burton; Athumani Ramadhani; Helen A Weiss; Victor Hu; Patrick Massae; Sarah E Burr; Wahida Shangali; Martin J Holland; David C W Mabey; Robin L Bailey
Journal:  Infect Immun       Date:  2011-09-12       Impact factor: 3.441

2.  Follicular trachoma and trichiasis prevalence in an urban community in The Gambia, West Africa: is there a need to include urban areas in national trachoma surveillance?

Authors:  E Quicke; A Sillah; E M Harding-Esch; A Last; H Joof; P Makalo; R L Bailey; S E Burr
Journal:  Trop Med Int Health       Date:  2013-09-06       Impact factor: 2.622

Review 3.  Trachoma: an update on prevention, diagnosis, and treatment.

Authors:  Satasuk Joy Bhosai; Robin L Bailey; Bruce D Gaynor; Thomas M Lietman
Journal:  Curr Opin Ophthalmol       Date:  2012-07       Impact factor: 3.761

4.  Using a nonparametric multilevel latent Markov model to evaluate diagnostics for trachoma.

Authors:  Artemis Koukounari; Irini Moustaki; Nicholas C Grassly; Isobel M Blake; María-Gloria Basáñez; Manoj Gambhir; David C W Mabey; Robin L Bailey; Matthew J Burton; Anthony W Solomon; Christl A Donnelly
Journal:  Am J Epidemiol       Date:  2013-04-01       Impact factor: 4.897

5.  Serology for trachoma surveillance after cessation of mass drug administration.

Authors:  Diana L Martin; Rhiannon Bid; Frank Sandi; E Brook Goodhew; Patrick A Massae; Augustin Lasway; Heiko Philippin; William Makupa; Sandra Molina; Martin J Holland; David C W Mabey; Chris Drakeley; Patrick J Lammie; Anthony W Solomon
Journal:  PLoS Negl Trop Dis       Date:  2015-02-25

Review 6.  Trachoma and Ocular Chlamydial Infection in the Era of Genomics.

Authors:  Tamsyn Derrick; Chrissy h Roberts; Anna R Last; Sarah E Burr; Martin J Holland
Journal:  Mediators Inflamm       Date:  2015-09-03       Impact factor: 4.711

7.  CT694 and pgp3 as serological tools for monitoring trachoma programs.

Authors:  E Brook Goodhew; Jeffrey W Priest; Delynn M Moss; Guangming Zhong; Beatriz Munoz; Harran Mkocha; Diana L Martin; Sheila K West; Charlotte Gaydos; Patrick J Lammie
Journal:  PLoS Negl Trop Dis       Date:  2012-11-01

Review 8.  Trachoma: protective and pathogenic ocular immune responses to Chlamydia trachomatis.

Authors:  Victor H Hu; Martin J Holland; Matthew J Burton
Journal:  PLoS Negl Trop Dis       Date:  2013-02-14

Review 9.  Will the SAFE strategy be sufficient to eliminate trachoma by 2020? Puzzlements and possible solutions.

Authors:  Diane K Lavett; Van C Lansingh; Marissa J Carter; Kristen A Eckert; Juan C Silva
Journal:  ScientificWorldJournal       Date:  2013-05-19

10.  Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia.

Authors:  Emma M Harding-Esch; Ansumana Sillah; Tansy Edwards; Sarah E Burr; John D Hart; Hassan Joof; Mass Laye; Pateh Makalo; Ahmed Manjang; Sandra Molina; Isatou Sarr-Sissoho; Thomas C Quinn; Tom Lietman; Martin J Holland; David Mabey; Sheila K West; Robin Bailey
Journal:  PLoS Negl Trop Dis       Date:  2013-06-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.